- £115.67m
- £105.47m
- £30.80m
- 31
- 16
- 24
- 12
RCS - Creo Medical Group - First use of Speedboat® UltraSlim in the USA
AnnouncementRCS - Creo Medical Group - First European Speedboat® UltraSlim procedure
AnnouncementREG - Creo Medical Group - Capital Markets Day
AnnouncementREG - Creo Medical Group - Speedboat® UltraSlim: US FDA Clearance
AnnouncementREG - Creo Medical Group - SB UltraSlim: EU launch accelerated by 18 months
AnnouncementREG - Creo Medical Group - Change of Nominated Adviser and Joint Broker
AnnouncementRCS - Creo Medical Group - Investor Presentation
AnnouncementREG - Creo Medical Group - Half-year Report
AnnouncementREG - Creo Medical Group - Notice of Results
AnnouncementRCS - Creo Medical Group - Royal Oldham SSD service update
AnnouncementREG - Creo Medical Group - Half Year Trading Update
AnnouncementREG - Creo Medical Group - Total Voting Rights
AnnouncementREG - AIM - AIM Notice - 27/07/2023
AnnouncementREG - Creo Medical Group - Award of Shares under Share Incentive Plan
AnnouncementREG - AIM - AIM Notice - 12/07/2023
AnnouncementREG - Creo Medical Group - Issue of Equity and TVR
AnnouncementREG - Creo Medical Group - Result of AGM
AnnouncementREG - Creo Medical Group - AGM Statement & Directorate Succession Planning
AnnouncementREG - Creo Medical Group - First upper GI Speedboat procedure in Europe
Announcement